DDAVP TABLETS 0.1MG

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DESMOPRESSIN ACETATE

Pieejams no:

FERRING INC

ATĶ kods:

H01BA02

SNN (starptautisko nepatentēto nosaukumu):

DESMOPRESSIN

Deva:

0.1MG

Zāļu forma:

TABLET

Kompozīcija:

DESMOPRESSIN ACETATE 0.1MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

30

Receptes veids:

Prescription

Ārstniecības joma:

PITUITARY

Produktu pārskats:

Active ingredient group (AIG) number: 0112050005; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2022-05-31

Produkta apraksts

_DDAVP Tablets 0.1 mg and 0.2 mg _
_Template Date: January 2010 _
_Page 1 of 29 _
PRODUCT MONOGRAPH
PR
DDAVP
® TABLETS
Desmopressin Acetate
0.1 mg and 0.2 mg Tablets
Antidiuretic
Ferring Inc.
200 Yorkland Boulevard
Suite 500
North York, Ontario
M2J 5C1
Date of Revision:
DECEMBER 17, 2015.
CONTROL NUMBER: 187744
_DDAVP Tablets 0.1 mg and 0.2 mg _
_Template Date: January 2010 _
_Page 2 of 29 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
CLINICAL TRIALS
............................................................................................